{"entity":{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","aka":[],"tldr":"A phase 3 trial of Florastamin F-18 run by FutureChem, active.","summary":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis is a phase 3 interventional study registered as NCT05004285 by FutureChem, with 398 participants planned, started 2021-04-28. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05004285","url":"https://clinicaltrials.gov/study/NCT05004285"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["florastamin-f18"],"companies":["futurechem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05004285","phase":"3","setting":"A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups","sponsor":"FutureChem","enrolled":398,"outcomes":[]},"route":"/trials/nct05004285/","neighbours":{"drug":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/"}],"company":[{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/"}]}}